Error message

An illegal choice has been detected. Please contact the site administrator.

Omnes Capital's exits

Sector 
Consumer goods
Entry Date 
2004
Exit Date 
2010
Buyer 
Azulis
Business 
Mezzanine Buyout & Growth Capital

Doucet

French manufacturer of homecare, insecticide and staining products

The Doucet group is one of France’s leading manufacturers of homecare, insecticide and staining products for businesses and consumers (Starwax, Kapo, Kiraviv and Purodor brands, sold predominantly in DIY superstores and drugstores). 

Sector 
Industry
Entry Date 
2008
Exit Date 
2010
Buyer 
Qualium
Business 
Small-Cap Buyout & Growth Capital

Sogal

Specialist wardrobe manufacturer

Established in La Jumellière (Maine-et-Loire department) since 1982, Sogal is one of France’s leading manufacturers of made-to-measure wardrobes, sliding doors and walk-in wardrobes.

Sector 
Business services
Entry Date 
2007
Exit Date 
2010
Buyer 
Management, Edmond de Rothschild Investment Partners
Business 
Small-Cap Buyout & Growth Capital

Ocean

Geolocation and corporate vehicle fleet management specialist

For the past ten years, Ocean has offered business intelligence solutions that maximise the efficiency of operational, administrative and financial management for both large groups and SMEs/micro-companies to bolster their development. Reports and charts available in real time facilitate decision-making and unlock concrete and quantifiable benefits.

Sector 
Construction and building materials
Entry Date 
2004
Exit Date 
2010
Buyer 
Dirickx Family
Business 
Mid-Cap Buyout & Growth Capital

Dirickx

International specialist in perimeter protection for sites

Founded in 1921, the Dirickx group is an international specialist in perimeter protection for sites offering a wide range of products and services for boundaries, entrances, access control and management, and security.

Latest news
Sector 
SaaS / Cloud
Entry Date 
2009
Exit Date 
2010
Buyer 
Cloudmark
Business 
Venture Capital

Bizanga

Specialist in email management

Bizanga, a specialist in email management, sold its IMP (Intelligent Message Processor) email traffic management platform to US partner Cloudmark. Bizanga retains its storage business and has changed its name to Bizanga Store.

Latest news
Sector 
Business services
Entry Date 
2006
Exit Date 
2009
Buyer 
Temenos
Business 
Small-Cap Buyout & Growth Capital

Viveo

Anti-money laundering solutions for banks

Software solutions for banks focused in particular on combating money-laundering. The sale to Swiss software vendor Temenos was among the largest deals in the European software vendor market in 2009.

Sector 
Industry
Entry Date 
2005
Exit Date 
2009
Buyer 
Groupe Charlois
Business 
Mid-Cap Buyout & Growth Capital

Saury

Company owned by four generations of coopers

Tonnellerie Saury joined the Charlois group, a family of stave producers for six generations, in December 2009. Production from the Charlois group’s two stave mills gives Tonnellerie Saury access to very high quality staves and ensures complete integration of the production chain.

Sector 
Pharma
Entry Date 
2006
Exit Date 
2009
Buyer 
Acquisition of a Pangenetics asset by Abbott
Business 
Venture Capital

PanGenetics

Development of innovative and unique humanised therapeutic antibodies.

Dutch company specialised in the clinical development of therapeutic antibodies. The company sold exclusive rights to its PG-110 antibody to Abbott for $190 million. Developed by PanGenetics, PG-110 is a humanised antibody targeting nerve growth factor (in phase I clinical trials). To date, the company has raised close to €51 million in the three funding rounds completed between 2005 and 2008. The deal is an endorsement of the company’s novel strategy predicated on the development of proprietary products and the licensing of new products, excluding R&D activities.

Sector 
Pharma
Entry Date 
2005
Exit Date 
2009
Buyer 
Sanofi Aventis
Business 
Venture Capital

Fovea Pharmaceuticals

Ocular franchise dedicated to discovering therapies for retinal conditions

Founded in 2005 to break new ground in the treatment of retinal conditions, Fovea Pharmaceuticals has built an R&D portfolio covering ocular conditions with unmet needs, and now forms Sanofi’s Ophthalmology division. Its core approach is to put patients at the heart of its strategy, thanks to its presence at the Institut de la Vision located on the Quinze-Vingts hospital campus. Its team consists almost exclusively of research scientists. 
The company was bought by Sanofi Aventis in 2009 in a deal worth up to €370 million.

 

Sector 
Pharma
Entry Date 
2004
Exit Date 
2009
Buyer 
Pharma Omnium International
Business 
Venture Capital

Mutabilis

Discovery of new therapeutic targets for the development of anti-infectives

Mutabilis is a biopharmaceutical company specialised in the discovery and development of anti-infectives. Mutabilis discovers and develops innovative anti-infectives, a novel class of drug addressing the current issues arising from resistance to antibiotics and targeting severe bacterial infections. Mutabilis’ new therapies target nosocomial infections in particular.

Pages

NewsRoom
No result found.